



Proposal for the new Board of Directors

C-RAD's election committee is proposing Brian Holch Kristensen as a new board member.

At the Annual General Meeting on April 16th 2014 the new board shall be elected. The election committee is proposing to replace Bengt Lind with Brian Holch Kristensen.

Brian Holch Kristensen is currently Chief Physicist at the radiation oncology department at Herlev Hospital, Danmark. After he received his degree in Physics and Mathematics in Aarhus he was working as a physicist at the Aarhus Center of Atomic Physics. After two years as the Deputy Chief Physicist in Herley, he became Chief Physicist in 2008.

Bengt Lind will, as planned, leave the board on his own wish.

Börje Bengtsson, Chairman of the Board, C-RAD AB:

"I would be glad to welcome Brian in the C-RAD board. In his role as a board member he would contribute with important clinical expertise to the successful work of the board. At the same time I thank Bengt Lind for his effort and his important contribution to develop the company."

The above information is price sensitive and must therefore be disclosed under the Securities Market Act (2077:528).

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 29 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel^{IM,} started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. For more information on C-RAD, please visit www.c-rad.com. Erik Penser Bankaktiebolag is appointed as C-RAD's Certified Adviser.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com